

AmeriHealth Caritas Pennsylvania Community Health Choices

Specifications for Gaps In Care

Short-term Adherence – Oral Diabetes Medicines

Purpose: The purpose of this measure is to identify and track members who are late in filling an oral diabetes medicine.

Who is Included? (denominator)	<ul style="list-style-type: none"> o Members with claims for single and multi- ingredient oral products used in the treatment of diabetes. Includes: sulfonylurea (e.g. glipizide), DPP-4 (e.g. sitagliptin), TZD (e.g. pioglitazone), biguanide (e.g. metformin), and alpha-glucosidase inhibitor (e.g. acarbose)
What Pharmacy Claim Data is evaluated? (numerator)	<ul style="list-style-type: none"> o Members who are between 20 and 100 days past their anticipated refill date
When does the analysis occur?	<ul style="list-style-type: none"> o Reviews claims from the previous 12 months o Updated Monthly
Where can I get this information?	<ul style="list-style-type: none"> o Monthly NaviNet report updates reflect Gaps In Care for PCP practice panel membership. o Quarterly printed reports sent to PCPs reflect Gaps In Care for PCP practice panel membership. o Panel membership results include indicators for this Gaps In Care measure as “At Risk”
Why does my member have an “At Risk” status?	<ul style="list-style-type: none"> o Pharmacy claims show an oral diabetes medicine is overdue for refill by 20 to 100 days.

Reference: Adherence Measures PDP/MA-PD Contracts Report User Guide. Acumen, LLC. July 2011.
 Available at: <https://PartD.ProgramInfo.US/PatientSafety>
 Last Updated on 02/06/2011

Revised: October 2017